Palantir’s Tectonic Shift: ARK Invest Accumulates as US Strength Masks Deepening European Fault Lines
28.06.2026 - 04:03:16 | boerse-global.de
A 45% haircut from its November 2025 peak has turned Palantir into a battleground stock. On one side, Cathie Wood’s ARK Invest waded into the carnage last week, snapping up 30,528 shares across three ETFs after the equity touched a new 52-week low of €93.30 on Thursday. On the other, company insiders have been heading for the exits, unloading $132.7 million worth of stock over the past three months. The Friday close at €99.40, good for a 5.35% bounce, was the strongest single-day gain of the week, but it still leaves the shares nursing a 10.95% seven-day loss and a year-to-date decline of roughly 31%.
That rebound came on the heels of an RSI reading of 35.2 – a level that puts the stock on the cusp of technically oversold territory. The distance to key moving averages underscores the severity of the selloff. Palantir is now trading about 15% below its 50-day average of €117.03 and roughly 27% under the 200-day line at €135.73. The all-time high of €179.98, set just eight months ago, looks distant. Support at the current 52-week floor of €93.30 remains the critical floor; a breach would open the door to further downside. On the upside, a reclaim of the 50-day moving average would be the first credible signal of a trend reversal, while the 100-day average at €119.69 represents the nearest meaningful resistance zone.
The buying from ARK – executed through the ARK Innovation, ARK Next Generation Internet, and ARK Blockchain & Fintech Innovation ETFs – is a clear vote of confidence from a prominent growth investor who sees the current valuation as a buying opportunity. And the fundamental case for Palantir’s US business is formidable. First-quarter 2026 revenue hit $1.633 billion, an 85% jump year-over-year, with the US segment surging 104% to $1.282 billion. Government clients contributed 84% growth, while US commercial revenue exploded 133%. For the full year, management lifted its revenue forecast to between $7.650 billion and $7.662 billion, with US commercial growth pegged at no less than 120% and free cash flow expected in the $4.2 billion to $4.4 billion range.
Two recent catalysts underpin that optimism. The US Army selected Palantir’s Foundry platform as the core data layer for its Next Generation Command and Control (NGC2) program, a central pillar of service-wide modernization. And a new seven-year partnership with Zeta Global, which is migrating its data infrastructure onto Palantir’s technology, carries an estimated annual revenue potential of over $100 million in the commercial segment. The analyst consensus price target of €160.40 implies roughly 61% upside from Friday’s close.
Should investors sell immediately? Or is it worth buying Palantir?
Yet the bull case runs headlong into Europe’s growing appetite for technological sovereignty – and the damage is already visible. France’s domestic intelligence agency, the DGSI, has announced plans to gradually replace Palantir’s data tools with those of local rival ChapsVision. While a contract extension signed in 2025 provides near-term protection, the strategic signal is unmistakable. Across the Channel, the UK’s NHS is reviewing its £330 million Federated Data Platform contract with Palantir, and parliamentary committees have urged the government to exercise an exit clause in February 2027, citing concerns over data control and foreign dependency.
These European defections are not merely reputational. They represent real revenue risk in a region where Palantir was already losing traction. The contrast with the US momentum could not be starker, and it explains why the stock remains stuck in a downward trajectory despite a succession of positive operational milestones. The insider selling spree – $132.7 million over three months – suggests that even those closest to the business are hedging their bets.
Two inflection points will shape the next leg of the story. The second-quarter 2026 earnings report, due later this summer, will test whether US commercial growth can sustain its triple-digit pace. A strong print could stabilise the stock above its recent low. The second catalyst is the NHS review, expected in early autumn. A formal decision to terminate the contract would not only hit revenues but could embolden other European governments to follow France’s lead, compounding the structural headwinds.
Palantir at a turning point? This analysis reveals what investors need to know now.
For now, Palantir remains a high-conviction bet on US AI adoption with a mounting European liability. ARK’s purchase is a tactical signal from a deep-value growth manager, but it has not yet moved the needle. Until the stock can recapture its 50-day moving average, every bounce looks vulnerable to the next wave of European sovereignty news.
Ad
Palantir Stock: New Analysis - 28 June
Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
